Belantamab Mafodotin-Based Triplet Elicits High Response Rates, Appears Suitable in Myeloma
December 8th 2020The ongoing phase 1/2 DREAMM-6 trial found that the addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.
MEDI-570 Evokes Durable Reponses in Patients with R/R T-Cell Lymphomas
December 8th 2020A phase 1 trial found that MEDI-570 demonstrated clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.